SCHEDULE: Avoro Capital Advisors Discloses 7.06% Stake in Hemab Therapeutics

Avoro Capital Advisors, Avoro Ventures, and Behzad Aghazadeh have collectively reported beneficial ownership of 7.06% of Hemab Therapeutics Holdings, Inc. common stock as of June 30, 2026.

Summary

• Avoro Capital Advisors LLC, Avoro Ventures LLC, and Behzad Aghazadeh (collectively, the 'Reporting Persons') have filed a Schedule 13G, indicating their beneficial ownership of Hemab Therapeutics Holdings, Inc. common stock.
• The total beneficial ownership reported is 5,221,322 shares, representing 7.06% of the outstanding common stock.
• This ownership is comprised of 1,925,150 shares held by Avoro Capital Advisors, 1,373,086 shares held by Avoro Ventures, and 3,298,236 shares held by Behzad Aghazadeh.
• The shares are held solely for investment purposes.
• The filing is based on 46,705,410 shares of common stock outstanding as of May 8, 2026, as reported in Hemab Therapeutics' Form 10-Q filed on May 21, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily indicating a significant but not controlling stake by investment entities. The lack of negative disclosures or immediate strategic shifts suggests a holding pattern rather than a strong conviction move.

Positives

• Significant investment by established entities (Avoro Capital Advisors, Avoro Ventures) suggests confidence in Hemab Therapeutics' long-term prospects.
• The reporting persons hold sole voting and dispositive power for their respective shares, indicating clear control over their investment decisions.
• The filing is routine and does not indicate any activist intentions or immediate disruptive strategies, which can be seen as a stable signal.

Negatives

• The filing does not provide any specific operational or financial updates, making it difficult to assess the underlying performance of Hemab Therapeutics.
• The aggregate ownership of 7.06% is a substantial stake but does not represent a controlling interest, leaving strategic direction potentially influenced by other major shareholders.

Risks

• The investment is subject to market risks and the general performance of Hemab Therapeutics' business, which are not detailed in this filing.
• Future changes in the reporting persons' investment strategy could lead to significant selling pressure on the stock.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or specific guidance regarding Hemab Therapeutics' future performance.

Management Comments

• The filing should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.
• The securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes. The healthcare and biotechnology sector, where Hemab Therapeutics operates, often sees such investment activity as firms identify potential growth opportunities.

Stakeholder Impact

• Shareholders: The increased stake by institutional investors may be viewed positively, potentially signaling confidence in the company's value. However, it does not immediately alter control or strategic direction.
• Management: The filing does not directly impact management's operational responsibilities but signifies that significant investors are closely monitoring the company's performance.

Next Steps

• The Reporting Persons will continue to hold their shares for investment purposes.
• Future amendments to the Schedule 13G will be filed if there are any changes in beneficial ownership or other reportable events.

Key Dates

Keywords

Hemab Therapeutics, Schedule 13G, Avoro Capital Advisors, Avoro Ventures, Behzad Aghazadeh, Beneficial Ownership, Investment, Common Stock